Last updated: April 3, 2026
What is the Drug Identified by NDC 67877-0901?
NDC 67877-0901 corresponds to Eptinezumab (Vyepti), a monoclonal antibody developed by Lundbeck that targets calcitonin gene-related peptide (CGRP) for the preventive treatment of migraines in adults.
Market Context and Growth Drivers
Current Market Size
- The global migraine treatment market was valued at approximately USD 4.6 billion in 2022.
- Prescriptions for CGRP inhibitors, including eptinezumab, constituted roughly 20% of the migraine drug market, with total revenue around USD 920 million in 2022.
Key Competitors
- Erenumab (Aimovig): Amgen/Novartis
- Fremanezumab (Ajovy): Teva
- Galcanezumab (Emgality): Eli Lilly
- Eptinezumab (Vyepti): Lundbeck
Market Penetration
- Eptinezumab received FDA approval in February 2020.
- The drug's intravenous administration provides an alternative to subcutaneous options, potentially appealing to patients with needle aversion or compliance issues.
- The market growth depends on physician adoption, insurance reimbursement, and clinical preference.
Pricing and Reimbursement Landscape
Current Price Point
- The average wholesale price (AWP) for a 300 mg IV dose is approximately USD 4,200 per infusion.
- Insurance reimbursement aims to align with these costs, influencing patient access and market penetration.
Reimbursement Policies
- CMS and private payers have started to include CGRP inhibitors under migraine management plans.
- Reimbursement rates vary by payer, with commercial plans generally covering up to 80-90% of the cost following formulary approval.
Price Trends
- Intravenous formulations tend to be priced higher than subcutaneous competitors, reflecting manufacturing costs.
- Market access pressures could drive prices downward over time, especially with increased competition.
Market Penetration and Adoption Projections
Short-Term (1-2 years)
- Market penetration remains limited, primarily driven by specialty neurologists.
- Estimated sales in 2023 projected at USD 150-200 million.
Mid-Term (3-5 years)
- As awareness grows and infusion centers expand, sales may increase to USD 400-600 million.
- The drug could account for 10-15% of the CGRP class, with annual growth rates of 20-25%.
Long-Term (5+ years)
- Potential expansion into broader migraine populations and off-label uses.
- Competition could reduce per-unit prices by 10-15% through increased bargaining power.
Price Projection Summary
| Year |
Estimated Revenue (USD millions) |
Average Price per Dose (USD) |
Key Assumptions |
| 2023 |
150-200 |
4,200 |
Limited insurance coverage |
| 2025 |
400-600 |
3,700 |
Increased market penetration |
| 2030 |
800-1,200 |
3,200 |
Market saturation, price erosion |
Key Factors Affecting Future Pricing
- Competitive pressure from lower-cost, subcutaneous CGRP inhibitors.
- Reimbursement adjustments favoring value-based pricing.
- Manufacturing innovations reducing costs.
- Changes in clinical guidelines expanding or restricting indications.
Key Takeaways
- NDC 67877-0901 (Eptinezumab) operates within a competitive migraine preventive market.
- Its intravenous administration and targeted mechanism support differentiated positioning.
- Price projections indicate a gradual decline in per-dose costs amid increasing adoption.
- Revenue growth depends on market access, payer policies, and clinical adoption.
- Long-term pricing will be influenced by competition, regulatory shifts, and innovation.
FAQs
Q1: How does eptinezumab pricing compare to other CGRP inhibitors?
A1: It is generally higher due to intravenous formulation; subcutaneous options range USD 6,000-8,000 annually, while eptinezumab's per-infusion price is approximately USD 4,200.
Q2: What factors could accelerate eptinezumab's market penetration?
A2: Increased physician awareness, expanded insurance coverage, and positive clinical outcomes could lead to faster uptake.
Q3: Are there potential discounts or value-based arrangements?
A3: Yes, payers may negotiate discounts or outcomes-based contracts to reduce costs.
Q4: Will new competitors impact the price of eptinezumab?
A4: Yes, new entrants or biosimilars could exert downward pressure on pricing over the next 3-5 years.
Q5: What is the outlook for long-term profitability?
A5: Profitability hinges on maintaining market share amidst price erosion and optimizing manufacturing efficiencies.
References
[1] Markets and Markets. (2023). Migraine Drugs Market.
[2] IQVIA. (2022). Migraine Market and Prescription Data.
[3] FDA. (2020). FDA Approval for Eptinezumab (Vyepti).
[4] Lundbeck. (2022). Vyepti Prescribing Information.
